Management of diabetes mellitus: Is the pump mightier than the pen?

Nature Reviews Endocrinology

Volumn 8, Issue 7, 2012, Pages 425-433

  Pickup, John C ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ISOPHANE INSULIN; LONG ACTING INSULIN;

BOLUS INJECTION; CANNULA; COMPUTER; COST EFFECTIVENESS ANALYSIS; DIABETIC KETOACIDOSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN TREATMENT; INTERMETHOD COMPARISON; MULTIPLE DAILY INSULIN INJECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATCH PUMP; PATIENT CARE; PATIENT EDUCATION; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIAL PSYCHOLOGY;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 84862501914     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.28     Document Type: Review

References (88)

1. Pickup, J. C., Keen, H., Parsons, J. A. & Alberti, K. G. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br. Med. J. 1, 204-207 (1978).
2. Philips, M., Simpson, R. W., Holman, R. R. & Turner, R. C. A simple and rational twice daily insulin regimen. Distinction between basal and meal insulin requirements. Q. J. Med. 48, 493-506 (1979).
3. Pickup, J. C. (Ed.) Insulin Pump Therapy and Continuous Glucose Monitoring, 1-116 (Oxford University Press, Oxford, 2009).
4. Mehta, S. N. & Wolsdorf, J. I. Contemporary management of type 1 diabetes. Endocr. Metab. Clin. North Am. 39, 573-593 (2010).
5. Paton, J. S., Wilson, M., Ireland, J. T. & Reith, S. B. Convenient pocket insulin syringe. Lancet 1, 189-190 (1981).
6. National Institute for Health and Clinical Excellence. Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus. Technology Appraisal Guidance 151 (Review of Technology Appraisal Guidance 57) (NICE, London, 2008).
7. Hirsch, I. B. Insulin analogues. N. Engl. J. Med. 352, 174-183 (2005).
8. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with Type 1 diabetes: dosage adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 325, 746-749 (2002).
9. Pickup, J. C. & Hammond, P. NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. Diabet. Med. 26, 1-4 (2009).
10. Lassman-Vague, V. et al. When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009. Diabet. Metab. 36, 79-85 (2010).
11. Pickup, J. C. & Sutton, A. J. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections versus continuous subcutaneous insulin infusion. Diabet. Med. 25, 765-774 (2008).
12. Cohen, D. et al. Continuous subcutaneous insulin infusion versus multiple daily injections in adolescents with type I diabetes mellitus: a randomized open crossover trial. J. Pediatr. Endocrinol. Metab. 16, 1047-1050 (2003).
13. Weintrob, N. et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 112, 559-564 (2003).
14. Hoogma, R. P. et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycemic control and quality of life: results of the 5-nations trial. Diabet. Med. 23, 141-147 (2006).
15. Pedersen-Bjergaard, U. et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab. Res. Rev. 20, 479-486 (2004).
16. Pankowska, E., Blazik, M., Dziechciarz, P., Szypowska, A. & Szajewska, H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomised controlled trials. Pediatr. Diabetes 10, 52-58 (2009).
17. Fatourechi, M. M. et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J. Clin. Endocr. Metab. 94, 729-740 (2009).
18. Pickup, J. C., Kidd, J., Burmiston, S. R. & Yemane, N. Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes: implications for NICE guidelines. Pract. Diabetes Int. 22, 10-14 (2005).
19. Pickup, J. C., Mattock, M. B. & Kerry, S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 324, 705-708 (2002).
20. Weissberg-Benchell, J., Antisdel-Lomaglio, J. & Seshadri, R. Insulin pump therapy: a meta-analysis. Diabetes Care 26, 1079-1087 (2003).
21. Misso, M. L., Egberts, K. J., Page, M., O'Connor, D. & Shaw, J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD005103. http://dx.doi.org/10.1002/14651858. CD005103.pub2 (2010).
22. Pickup, J. C., Kidd, J., Burmiston, S. & Yemane, N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab. Res. Rev. 22, 232-237 (2006).
23. Hammond, P. NICE guidance on insulin pump therapy: time for a re-appraisal? Pract. Diabetes Int. 22, 115-116 (2005).
24. Retnakaran, R. et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 27, 2590-2596 (2004).
25. [No authors listed] The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45, 1289-1298 (1996).
26. Pickup, J. C. in Oxford Textbook of Endocrinology and Diabetes, 2nd edn (eds Wass, J. A. & Stewart, P. M.) 1861-1868 (Oxford University Press, Oxford, 2011).
27. Bruttomesso, D. et al. In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet. Med. 25, 326-332 (2008).
28. Lauritzen, T., Pramming, S., Deckert, T. & Binder, C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 24, 326-329 (1983).
29. Pickup, J. C. & Renard, E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 31 (Suppl. 2), S140-S145 (2008).
30. Doyle, E. A. et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 27, 1554-1558 (2004).
31. Hirsch, I. B. et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injections of insulin aspart/insulin glargine in type 1 diabetic patients previously untreated with CSII. Diabetes Care 28, 533-538 (2005).
32. Bolli, G. B. et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 32, 1170-1176 (2009).
33. DeVries, J. H. Will long-acting insulin analogues influence the use of insulin pump therapy in type 1 diabetes? Curr. Diabetes Rev. 1, 23-26 (2005).
34. Warren, E., Weatherley-Jones, E., Chilcott, J. & Beverley, C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol. Assess. 8, 1-57 (2004).
35. Home, P. et al. Insulin detemir offers improved glycemic control compared to NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27, 1081-1087 (2004).
36. Tsui, E., Barnie, A., Ross, S., Parkes, R. & Zinman, B. Intensive insulin therapy with insulin lispro: a randomised trial of continuous subcutaneous insulin infusion versus multiple daily injections. Diabetes Care 24, 1722-1727 (2001).
37. DeVries, J. H., Snoek, F. J., Kostense, P. J., Masurel, N. & Heine, R. J. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25, 2074-2080 (2002).
38. Linkeschova, R., Raoul, M., Bott, U., Berger, M. & Spraul, M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet. Med. 19, 746-751 (2002).
39. Pickup, J. C. & Harris, A. Assessing quality of life for new diabetes treatments and technologies: a simple patient-centered score. J. Diabetes Sci. Technol. 1, 394-399 (2007).
40. McMahon, S. K. et al. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. Diabet. Med. 22, 92-96 (2005).
41. Müller-Godeffroy, E., Treichel, S. & Wagner, V. M. Investigation of quality of life and family burden issues during insulin pump therapy in children with type 1 diabetes mellitus-a large scale multicentre pilot study. Diabet. Med. 26, 493-501 (2009).
42. Knight, S. et al. Improvements in cognition, mood and behaviour following commencement of continuous subcutaneous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study. Diabetologia 52, 193-198 (2009).
43. Hammond, P., Liebl, A. & Grunder, S. International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion on glucose control and quality of life. Prim. Care Diabetes 1, 143-146 (2007).
44. Nixon, R. & Pickup, J. C. Fear of hypoglycemia in type 1 diabetes managed by continuous subcutaneous insulin infusion: is it associated with poor glycemic control? Diabetes Technol. Ther. 13, 93-98 (2011).
45. Aberle, I. et al. Psychological aspects in continuous subcutaneous insulin infusion: a retrospective study. J. Psychol. 143, 147-160 (2009).
46. Bruttomesso, D. et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet. Med. 19, 628-634 (2002).
47. Hughes, C. R., McDowell, N., Cody, D. & Costigan, C. Sustained benefits of continuous subcutaneous insulin infusion. Arch. Dis. Child. 97, 245-247 (2012).
48. Home, P. D. et al. Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or injection of the augmented mealtime dose. Metabolism 30, 439-442 (1981).
49. Jones, S. M., Quarry, J. L., Caldwell-McMillan, M., Mauger, D. T. & Gabbay, R. A. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol. Ther. 7, 233-240 (2005).
50. Heinemann, L. Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements? J. Diabet. Sci. Technol. 3, 1490-1500 (2009).
51. Shashaj, B., Busetto, E. & Sulli, N. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of pediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet. Med. 25, 1036-1042 (2008).
52. Corriveau, E. A. et al. Effect of Carelink, an internet-based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatr. Diabetes 9, 360-366 (2008).
53. Klonoff, D. C. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28, 1231-1239 (2005).
54. Pickup, J. C., Freeman, S. C. & Sutton, A. J. Glycaemic control in type 1 diabetes during real-time continuous glucose monitoring compared to self-monitoring of blood glucose: meta-analysis of randomized controlled trials using individual patient data. BMJ 343, d3805 (2011).
55. Battelino, T. et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 34, 795-800 (2011).
56. Choudhary, P. et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 34, 2023-2025 (2011).
57. Pickup, J. C. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps. Diabetes Technol. Ther. 13, 695-698 (2011).
58. Wollitzer, A. D., Zisser, H. & Jovanovic, L. Insulin pumps and their use in pregnancy. Diabetes Technol. Ther. 12 (Suppl. 1), S33-S36 (2010).
59. Hammond, P. in Insulin Pump Therapy and Continuous Glucose Monitoring, Ch. 6 (ed. Pickup, J.) 69-77 (Oxford University Press, Oxford, 2009).
60. Mukhopadhyay, A., Farrell, T., Fraser, R. B. & Ola, B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and meta-analysis of randomized, controlled trials. Am. J. Obstet. Gynecol. 197, 447-456 (2007).
61. Chen, R. et al. Level of glycemic control and pregnancy outcome in type 1 diabetes: comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am. J. Obstet. Gynecol. 197, 404-406 (2007).
62. González-Romero, S. et al. Continuous subcutaneous insulin infusion versus multiple daily injections in pregnant women with type 1 diabetes. Diabetes Technol. Ther. 12, 263-269 (2010).
63. Anhalt, H. & Bohannon, N. J. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol. Ther. 12 (Suppl. 1), S51-S58 (2010).
64. Roze, S., Valentine, W. J., Zakrzewska, K. E. & Palmer, A. J. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet. Med. 22, 1239-1245 (2005).
65. Cohen, N. et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Phamacoeconomics 25, 881-897 (2007).
66. Cummins, E. et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol. Assess. 14, 1-181 (2010).
67. St Charles, M. E., Sadri, H., Minshall, M. E. & Tunis, S. L. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clin. Ther. 31, 657-667 (2009).
68. Bruttomesso, D., Costa, S. & Baritussio, A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab. Res. Rev. 25, 99-111 (2009).
69. Raskin, P. et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 26, 2598-2603 (2003).
70. Wainstein, J. et al. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet. Med. 22, 1037-1046 (2005).
71. Herman, W. H. et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 28, 1568-1573 (2005).
72. Berthe, E. et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous insulin infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm. Metab. Res. 39, 224-229 (2007).
73. Davidson, P. C., Jeng, L., Ghegan, M., Winsett, J. & Bode, B. W. Continuous subcutaneous insulin infusion for treatment of type 2 diabetes mellitus [abstract]. Diabetologia 42 (Suppl. 1), 796 (1999).
74. Wainstein, J., Metzger, M., Wexler, I. D., Cohen, J. & Raz, I. The use of continuous insulin delivery systems in severely insulin-resistant patients. Diabetes Care 24, 1299 (2001).
75. De Borst, J. M. & Berghout, A. Continuous subcutaneous insulin infusion in diabetes mellitus type 1 and 2: lower HbA1c-values and a high level of patient satisfaction [Dutch]. Ned. Tijdschr. Gen. 147, 2021-2025 (2003).
76. Nielsen, S. et al. Use of continuous subcutaneous insulin infusion pump in patients with type 2 diabetes mellitus. Diabetes Educ. 31, 843-848 (2005).
77. Kesavadev, J., Balakrishnan, S., Ahammed, S. & Jothydev, S. Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes. Diabetes Technol. Ther. 11, 517-521 (2009).
78. Edelman, S. V. et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol. Ther. 12, 627-633 (2010).
79. Gentry, C. K., Cross, L. B., Gross, B. N., McFarland, M. S. & Besterman, W. H. Retrospective analysis and patient satisfaction assessment of insulin pump therapy in patients with type 2 diabetes. South Med. J. 104, 24-28 (2011).
80. Peyrot, M., Rubin, R. R., Chen, X. & Frias, J. P. Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus. Diabetes Technol. Ther. 13, 471-476 (2011).
81. Reznik, Y. et al. Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up. Diabetes Technol. Ther. 12, 931-936 (2010).
82. Lane, W. S., Weinrib, S. L., Rappaport, J. M. & Przestrzelski, T. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and insulin resistance. Endocr. Pract. 16, 778-784 (2010).
83. Wolff-McDonagh, P. et al. Using insulin pump therapy in poorly controlled type 2 diabetes. Diabetes Educ. 36, 657-665 (2010).
84. Wu, Y. P., Graves, M. M., Roberts, M. C. & Mitchell, A. C. Is insulin pump therapy better than injection for adolescents with diabetes? Diabetes Res. Clin. Pract. 89, 121-125 (2010).
85. Boland, E. A., Grey, M., Oesterle, A., Fredrickson, L. & Tamborlane, W. V. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 22, 1779-1784 (1999).
86. Pickup, J. C. Are insulin pumps underutilized in type 1 diabetes? Yes. Diabetes Care 29, 1449-1452 (2006).
87. Kordonouri, O. et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results from the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 53, 2487-2495 (2010).
88. Sulmont, V. et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment? J. Pediatr. 157, 103-107 (2010).